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Summary We describe a quantitative histological study of 34 breast biopsies using a marker for human
macrophages, the monoclonal antibody EBM/11. Seventeen of the biopsies were of malignant tumours. Both
benign and malignant breast tissue contained large numbers of macrophages with significantly higher numbers
occurring in the malignant group. An analysis was made of macrophage counts according to stage, grade and
prognostic index of the malignant tumours. There was no correlation between macrophage numbers and any
of these parameters in malignant breast tumours. We discuss the possible reasons why some earlier studies
(using other markers such as lysozyme), have shown an apparently insignificant number of intratumoral
macrophages.
Most malignant tumours are infiltrated by inflammatory
cells and it has long been considered that such infiltrates
may be evidence of a host response to the tumour (Eccles &
Alexander, 1974: Hamlin, 1968). Among tumours where such
a response is of particular interest is human mammary
carcinoma which has the potential for metastasis at a
relatively early stage of the disease and in which metastases
may appear many years after apparently adequate local
treatment. Although lymphocytes are prominent in the
inflammatory infiltrate, macrophages are also present, often
in considerable numbers (McBride, 1986; Steele et al. 1985;
Lwin, et al. 1986). It has been suggested that the presence of
macrophages may independently influence the outcome by
affecting the metastatic potential of tumours (Lauder et al.,
1977) and there is evidence from experimental animal
tumours that this is so (Fidler & Poste, 1982; Eccles &
Alexander, 1974; Wood & Gillespie, 1975). However, others
have found otherwise; for example, in the case of murine
mammary carcinoma (Nash et al., 1979). In vitro studies
have shown a tumoricidal effect of human macrophages on a
variety of human tumour lines including mammary
carcinoma (Sone et al., 1984, 1985).
One approach to the investigation of the role of macro-
phages in human oncology is their quantitation in tumour
material obtained at surgery. This approach has been
hampered by the difficulty of identifying macrophages in
standard histological preparations of tumours. This has led
to the use of various markers to assist in their identification
(McBride, 1986). In the studies reported to date, the markers
used have lacked specificity for cells belonging to the mono-
nuclear phagocyte system (MPS). For example, Fc and C3
receptors are also found on B-lymphocytes (Boston, 1972;
Tubbs et al., 1979) and their demonstration is technically
demanding. Both lysozyme (Mason & Taylor, 1975) and
alpha-l antitrypsin are found in granulocytes (Isaacson et al.,
1981; Benitez-Bibiesca & Frere-Horta et al., 1978) and
lysozyme has been found in carcinoma cells (Tahara et al.,
1982). Enzymes such as acid phosphatase and alpha-
naphthyl acetate esterase (ANAE), demonstrated by histo-
chemical techniques, are also not specific and may be found
in a variety of tumours including, in the case of ANAE,
mammary carcinoma (Tubbs et al., 1979). More recently, a
variety of monoclonal antibodies with activity against MPS
cells have been used in studies of tumour infiltrates (Steele et
al., 1985; Lwin et al., 1985). Among the drawbacks
associated with the use of such antibodies, however, is failure
to detect all tissue macrophages as in the case of UCHM-1
(Hogg et al., 1984) used in the study of Lwin et al. (1985) or
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reactivity with non-MPS elements such as granulocytes as in
the case of VEP-7 (Kraft et al., 1981), the antibody used in
the study of Steele et al. (1985).
We report here the results of a quantitative study of
macrophages in benign and malignant breast disease using
the mouse monoclonal antibody EBM/11 which has high
cellular specificity for cells of the human MPS. A full
account of this antibody, which was raised against human
alveolar macrophages, is contained in Kelly et al. (1987) (see
also Bliss et al., 1984). Briefly, in an extensive tissue screen it
showed reactivity against an epitope present in the cytoplasm
of all members of the human mononuclear phagocyte system
including peripheral blood monocytes, alveolar macrophages,
Kupffer cells, splenic littoral cells, sinusoidal and germinal
centre macrophages and also interdigitating reticulum cells in
lymph nodes and microglial cells in the brain. Reactivity was
also noted with macrophages in gut, dermis, liver, portal
tracts, thyroid and kidney. There is also reactivity with other
cells of bone marrow origin including osteoclasts, mega-
karyocytes and platelets (Athanasou et al., 1986). However,
both in tissue sections and in peripheral blood films, there is
no reactivity with granulocytes or lymphocytes. In monocyte
enriched preparations from peripheral blood virtually all
cells stained with the exception of a few contaminating,
morphologically recognizable lymphocytes. In the tissue
screen, the only non myeloid element which showed weak
reactivity was proximal renal tubule cells. No other epithelial
cell stained. Endothelial cells did not stain. The antibody has
been considered in the myeloid panel of the Third Inter-
national Workshop on Human Leucocyte Differentiation
Antigens, where it was assigned to Group 12, the mixed anti-
macrophage group. Within this group, it is included in
subgroup 4 which includes those antibodies with broad
specificity (Hogg & Horton, 1987). Unlike many of the
antibodies in this group EBM/1 1 shows strong reactivity
with peripheral blood monocytes (Kelly et al., 1987).
Materials and methods
Thirty-four biopsies were studied. They were excision
biopsies of clinically suspicious breast lesions which had been
submitted for frozen section diagnosis. A portion of each
biopsy was snap frozen in liquid nitrogen and stored at
-70°C. Cryostat sections (6,um) were cut, air-dried and
fixed in cold acetone for 30min. Sections were incubated in
tris-buffered saline (TBS), pH 7.4 with 20% pooled normal
human serum before incubation with the primary antibody,
EBM/11 (culture supernatant, 1:10 in TBS) for 30 min at
22°C. Negative controls were provided by substituting TBS
for the primary antibody. Following washing in TBS for
10min. a standard three stage immunoperoxidase technique
was followed using diaminobenzidine (DAB) as a chromogen
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(Gatter et al., 1984). In each case, frozen section diagnosis
was confirmed by examining routine paraffin sections from
the original frozen block which had been fixed in formal
saline and embedded. In selected cases sections from the
frozen paraffin blocks were stained using a polyclonal
antibody to lysozyme (Hoechst: 1:200 in TBS). In cases of
carcinoma, staging of the disease was determined following
pathological examination of subsequent mastectomy and
axillary lymph node specimens. In one case, segmental
mastectomy was performed without axillary lymph node
sampling. In this case, the staging was based on the
assumption that the nodes were negative in accordance with
the clinical findings. The tumours were graded histologically
according to the criteria of Bloom & Richardson (1957).
Pathological staging and histological grade were also
combined into a prognostic index (PI) according to the
simplified formula of Haybittle et al. (1982).
Macrophages, identified by positivity for EBM/11, were
counted by projecting a high power microscope field onto a
touch sensitive pad attached to a MOP-AMO3 (Kontron,
German Federal Republic) image analyser. Three fields from
the centre of the tumour were counted by each observer and
the result was expressed as an average of the three.
There was high concordance between the results. In the
malignant cases, a count was also made of tumour cells in
the same fields. U Test Counting was done independently by
two observers. Each counted three fields from each section.
In the tumour cases, the sections were from the main tumour
mass. Fields were selected at random from the tumour
sections and those counted consisted completely of tumour
including stroma. Areas of necrosis were avoided. In
malignant cases, a count was also made of tumour cells in
the same fields. The second count was used as a check of
consistency of the first. As three different random fields were
chosen, it was also a test of how representative of the
tumour the first sample was. There was high concordance
between the results obtained by the two observers. This
provided objective support for the subjective impression of
little field-to-field variation in macrophage distribution
within individual tumours (see Results).
The differences in macrophage count between the various
subgroups were compared using the Mann-Whitney U Test.
Results
Of the 34 cases studied, 17 were of benign disease [mean age
42.25 years (range: 37-57)]. All consisted of 'fibrocystic'
disease, apart from one tubular adenoma and one case of
gynaecomastia. The highest macrophage count in the benign
group was in a case of sclerosing adenosis occurring in a
pregnant woman. The remaining 17 cases were of malignant
disease [mean age 56 years (41-70)]. The findings are
summarised in Table I. Follow-up records were available for
14 of the carcinoma patients. The average period of follow-
up was 24.1 months (range 4-33). No local recurrence or
distant metastasis was recorded in that period.
Cells which were morphologically consistent with macro-
phages showed strong positivity on immunohistochemical
staining with EBM/11. The corresponding cells in negative
control sections remained unstained. Positive cells showed a
uniform intensity of staining with little cell-to-cell
variation. Mixed among the positively stained macrophages
were other inflammatory cells such as lymphocytes, plasma
cells and neutrophils. These were uniformly negative.
The macrophage counts for both groups are summarised
in Table II. There is a significant difference in score between
the benign and malignant groups, although the range for
both is strikingly wide. In the malignant group macrophage
counts showed no significant difference when stratified
Table I Summary of pathological stage and histological types and
grade of 17 cases of breast carcinoma
Clinico-
pathological Histological
stage grade
Histological type I II Total I II III Total
Lobular carcinoma
in situ 1 1 1 1
Infiltrating lobular
carcinoma 1 1 1
Infiltrating ductal
carcinoma 7 8 15 2 7 6 15
Totals 9 8 17 4 7 6 17
Table II Macrophage counts (per HPF) in benign and malignant
breast tissue
M+% of
epithelial
Meana (Range) or tumour cells (Range)
Benign (n= 17) 54 (15-183) 25 (2-120)
Malignant (n= 17) 99 (21-185) 53 (7-139)
p<o.05
aAverage of three high power fields.
according to pathological stage (Table III) histological grade
(Table IV) or prognostic index (Table V). In the absence of
any recurrence, no attempt could be made to establish a
relationship between macrophage count and this important
determinant of disease activity, although such a relationship
may become apparent with more prolonged follow-up.
Amongst the carcinomas, macrophages were found
throughout the tumour both in the stroma and with tumour
cell nests. Where sections included the junction between
tumour and 'normal' breast there was no tendency for
macrophages to collect at the tumour periphery. Many
tumours contained very large numbers of macrophages
which in some instances clearly outnumbered tumour cells
(Table II). Within individual tumours the macrophage count
was generally consistent throughout with only slight field-to-
field variability. In no case was there staining of malignant
cells by EBM/1. In some tumours, macrophages were more
numerous in the stroma and appeared to infiltrate the
tumour focally in a fashion resembling 'piecemeal necrosis'
of the liver (Figure 1).
Although the sample from each case, three high power
microscopic fields, was small, the concordance between the
counts of the two observers indicated that the sample was
adequate and representative.
In the cases where lysozyme was used as a marker for
macrophages for comparison with EBM/11 many fewer
positive cells were found overall. Those present were most
numerous at the periphery of the tumour, in areas of
necrosis and also within fibrous septa within the tumour,
although some intraepithelial macrophages were also found
(Figure 2).
Discussion
This study demonstrates the presence, in significant numbers,
ofmacrophages in breast tissue in both benign and malignant
disease. Within both groups there is wide variation in
numbers but there is, nevertheless, a significant excess in
malignant tumours. The highest count, by far, in the benign176 P.M.A. KELLY et al.
Table III Macrophage counts in malignant
breast tumours according to pathological
stage at presentation
Stage Mean Range
I (n=9) 96 21-173
II (n=8) 102 50-185
Not significant.
Table IV Macrophage counts in malignant
breast tumours according to histological
grade
Grade Mean Range
I (n=4) 74 46- 92
II (n=8) 97 21-185
III (n=5) 123 75-173
I vs. II; II vs. III; I vs. III; 1 +II vs. III; I vs.
II+III: all NS.
Table V Macrophage count according to
prognostic index
PI Mean Range
A (n=5) 91 21-185
B (n=9) 115 50-173
C (n=2) 134 110-157
A<3.4 C>5.4
A vs. B; B vs. C; A vs. C; A+B vs. C; A vs.
B+C: all NS.
Figure 1 A cryostat section of infiltrating ductal carcinoma
which includes the edge of the tumour. Abundant EBM/1 1 +
macrophages are present throughout the tumour and are seen to
extend into it from the periphery in a fashion reminiscent of
'piecemeal necrosis' (arrow) (Immunoperoxidase x 32).
group was in a biopsy from a pregnant woman which
showed sclerosing adenosis. In the malignant group, there is
no correlation between pathological stage, histological grade
or prognostic index and macrophage count, although the
numbers in each group are small. In the period of follow-up,
no recurrence was documented although the average follow-
up, at just over two years is relatively short in the natural
history of this disease.
The finding of large numbers of macrophages within
benign and malignant breast tissue is in accordance with
Figure 2 A similar field to Figure 1 showing macrophages
stained for lysozyme. There are many fewer positive cells. Those
present are most numerous at the edge of the tumour or in
fibrous septa with only scattered intra-tumoral macrophages
(Immunoperoxidase x 32).
recent observations by Lwin et al. (1985), Ferguson (1985),
and Steele et al. (1985). We also observed a significant
number of intraepithelial macrophages in benign breast
tissue as well as within tumour epithelium (Lwin et al.,
1985). We did not quantitate separately intraepithelial and
stromal macrophages in tumours as, especially in the
diffusely infiltrative or solid tumours, the distinction would
have been arbitrary. However, on subjective assessment, in
some tumours the macrophages were predominantly stromal
whereas, in others the distribution was more diffuse. There is
a disparity between our findings and those of workers who
have studied macrophage infiltration of mammary carcinoma
using lysozyme as a marker (Nash, 1981; Tanaka et al.,
1986). These studies showed the presence of small numbers
of macrophages associated with the tumours which were
localized mainly at the periphery. In the cases which we
studied using lysozyme, our findings were similar to those
reported but were in marked contrast to those with EBM/ 1.
This is not attributable to differences in fixation and
processing as, in a separate study, we have found that
routine fixation in formalin and processing through to
paraffin does not affect reactivity with the polyclonal
antibody which was used in this study (Kelly, in
preparation). The difference in macrophage numbers found
using the two different antibodies suggests that many
macrophages in tumours are either depleted of lysozyme
because of rapid turnover or that some are no longer
synthesizing it in immunohistochemically-detectable quan-
tities. The persistence of lysozyme containing macrophages in
some parts of tumours, i.e. in areas of necrosis and at the
periphery, further suggests a functional dichotomy in that
many fewer lysozyme positive macrophages are found in
intimate contact with tumour cells or in tumour stroma. We
have noted a similar depletion of lysozyme containing
Kupffer cells in alcoholic liver biopsies although there is no
reduction in absolute Kupffer cell numbers in these livers
using EBM/11 as a marker (Kelly, in preparation). Clearly,
therefore, lysozyme is not a reliable marker for use alone in
quantitative histological studies of macrophages although
when used in parallel with a marker such as EBM/11, it may
give a useful insight into the functional state of MPS cells in
various disease states.
The role of macrophages in tumours in general and
specifically in breast tumours is not fully understood. It is
clear that this role is not a simple one and that tumour
associated macrophages (TAM) are functionally hetero-
geneous (McBride, 1986). The balance of evidence from
experimental studies supports the notion that macrophages
do have a role in limiting metastasis and that this function
can be carried out without help from other immuno-MACROPHAGES IN BREAST DISEASE 177
competent cells (Fidler & Poste, 1982), although in vivo the
invariable association of lymphocytes with macrophages in
tumours cannot be ignored. The finding in this study of
large numbers of macrophages within malignant breast
tumours including the tumour epithelium itself, the so called
'neoplastic compartment' (Whitwell et al., 1984), is not
inconsistent with the concept of anti-tumour activity of
TAM although we recognise the dangers of making
inferences about function from static morphological studies
such as this.
This study also demonstrates the usefulness of a
monoclonal antibody such as EBM/ 1I as a marker for
macrophages in immunohistochemical investigations of
malignant tumours. Its use has highlighted the presence of a
large component of MPS cells within malignant breast
tumours. The number of such cells was not apparent and
certainly not quantifiable on conventional staining and
would have been seriously underestimated if a marker such
as lysozyme had been used.
We thank Miss Lesley Watts for typing the manuscript. PMAK
holds a travelling studentship from the National University of
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